Doherty David T 4
4 · Surgery Partners, Inc. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Surgery Partners (SGRY) CFO David Doherty Receives RSAs, Sells Shares
What Happened
David T. Doherty, Chief Financial Officer of Surgery Partners (SGRY), received three restricted stock awards (RSAs) on March 5, 2026 totaling 141,743 shares valued at $1,999,994 (56,697; 54,545; 30,501 shares at $14.11 each). He also disposed of 14,574 shares on March 6, 2026 in an open-market/private sale for a weighted average price of $13.84, generating $201,704. The sale was executed to satisfy tax-withholding obligations related to RSA vesting and is routine (not a discretionary purchase).
Key Details
- Grant date(s): March 5, 2026 — three RSA grants totaling 141,743 shares; aggregate value ~$1,999,994.
- Sale: March 6, 2026 — 14,574 shares sold @ weighted avg $13.84 = $201,704.
- Vesting: Grants have differing schedules — one vests in three equal annual installments beginning on the first anniversary, one vests on the first anniversary, and one vests on the second anniversary.
- Sale purpose: Shares sold to satisfy tax withholding for RSAs that vested Feb 28 and Mar 2, 2026 (tax-withholding sale).
- Weighted average price: The sale price reported is a weighted average; the filer can provide per-price details on request.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Filing timeliness: Form 4 filed March 9, 2026; appears timely given the March 5–6 transaction dates.
Context
RSAs are equity grants that vest over time; these awards represent compensation rather than open-market purchases (so they are not a direct bullish signal). The small sale was solely to cover tax obligations and is routine. Purchases or open-market buys tend to carry more weight when gauging insider sentiment; this filing mainly documents grant-based compensation and related withholding.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-06$13.84/sh−14,574$201,704→ 88,803 total - Award
Common Stock
[F3]2026-03-05$14.11/sh+56,697$799,995→ 145,500 total - Award
Common Stock
[F4]2026-03-05$14.11/sh+54,545$769,630→ 200,045 total - Award
Common Stock
[F5]2026-03-05$14.11/sh+30,501$430,369→ 230,546 total
Footnotes (5)
- [F1]Shares sold to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock on February 28, 2026 and March 2, 2026.
- [F2]The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest in three equal annual installments beginning on the first anniversary of the Grant Date.
- [F4]Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the first anniversary of the Grant Date.
- [F5]Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the second anniversary of the Grant Date.